Last reviewed 2026-04-20 · How we verify

Mounjaro

At a glance

Approved indications

• Diabetes mellitus type 2

Common side effects

• Gastrointestinal adverse reactions (15 mg)
• Gastrointestinal adverse reactions (10 mg)
• Gastrointestinal adverse reactions (5 mg)
• Nausea
• Diarrhea
• Decreased appetite
• Vomiting
• Constipation
• Dyspepsia
• Abdominal pain

Key clinical trials

• Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment (NA)
• Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese (PHASE2)
• Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder (PHASE2)
• Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes (PHASE3)
• GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial (PHASE2, PHASE3)
• Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder (PHASE2)
• Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs (NA)
• Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Mounjaro CI brief — competitive landscape report
• Mounjaro updates RSS · CI watch RSS
• Nicholas Skertich portfolio CI